期刊文献+

晚期前列腺癌药物治疗新进展 被引量:2

New progress in research of drugs for advanced prostate cancer
原文传递
导出
摘要 前列腺癌由于发病率、死亡率逐年升高,正已成为肿瘤防治最受关注的恶性肿瘤之一。晚期前列腺癌患者的规范化药物治疗是提高患者生存时间、改善生活质量的关键因素。本文将近年来有关晚期前列腺癌特别是去势抵抗性前列腺癌患者药物治疗的最新进展进行简要介绍,以利于医师在临床工作中选择合理药物及治疗方案。 The incidence and mortality of prostate cancer have increased steadily, becoming a hot-point in cancer research. For advanced prostate cancer, especially castration-resistant prostate cancer (CRPC), the stand- ard drug therapy is the key to improve the survival time and the quality of life. This article interpreted the drugs and clinical treatment options in recent years.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第17期2030-2034,共5页 Chinese Journal of New Drugs
关键词 晚期前列腺癌 去势抵抗性前列腺癌 药物治疗 进展 advanced prostate cancer castration-resistant prostate cancer drug treatment progress
  • 相关文献

参考文献23

  • 1TANNOCK IF, DE WIT R, BERRY WR, et al, Docctaxcl plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N EnglJ Med ,2004,351 (15) : 1502 - 1512. 被引量:1
  • 2PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J] . N EnglJ Med ,2004, 351 (15) : 1513 - 1520. 被引量:1
  • 3周爱萍,房虹,李长岭,孙燕.去势抗拒前列腺癌治疗新药卡巴他赛[J].中国新药杂志,2013,22(19):2229-2231. 被引量:10
  • 4DE BONOJS, OUDARD S, OZGUROGLU M, et al. Prednisone pluscabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial[J] . Lancet ,2010 ,376 (9747) : 1147 - 1154. 被引量:1
  • 5HARZSTARK AL, ROSENBERGJE, WEINBERG VK, et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancerafter docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clin- ical Trials Consortium[J]. Cancer ,2011 ,1l7( 11) :2419 -2425. 被引量:1
  • 6HERNANDEZ-AYA L, HUSSAIN M. Metastatic hormone-sensitive and castration-resistant prostate cancer: a decade of progress, ongoing discoveries, genitourinary cancers symposium[R]. Chicago: ASCO ,2014. 被引量:1
  • 7CHEN CD, WELSBIE DS, TRAN C, et al. Molecular determinants of resistance to antiandrogentherapy[J]. Nat Med, 2004,10 (1):33-39. 被引量:1
  • 8W ALTERING KK, HELENIUS MA, SAHU B, et al, Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens[J]. Cancer Res,2009,69(20) :8141- 8149. 被引量:1
  • 9周爱萍,房虹,李长岭,孙燕.去势抗拒前列腺癌治疗新药醋酸阿比特龙[J].中国新药杂志,2013,22(17):1998-2001. 被引量:6
  • 10DE BONO rs, LOGOTHETIS CJ, MOLINA A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N EnglJ Med, 2011,364(21) :1995 -2005. 被引量:1

二级参考文献18

  • 1HWANG C. Overcoming docetaxel resistance in prostate cancer: a perspective review[J]. Ther Adv Med Oncol , 2012,4(6):329-340. 被引量:1
  • 2MITA AC, DENIS LJ, ROWINSKY EK, et al. Phase Ⅰ and phar- macokinetic study of XRP6258 (RPR 116258A) , a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors [ J 1. Clin Cancer Res ,2009,15 (2) :723 - 730. 被引量:1
  • 3PIVOT X, KORALEWSKI P, HIDALGO JL,et al. A muhicenter phase Ⅱ study of XRP6258 administered as a 1-h i. v. infusion ev- ery 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008,19(9) :1547 - 1552. 被引量:1
  • 4DE BONO JS, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxe! treatment: a randomised open-label trial [ J ]. Lancet, 2010,376 ( 9747 ) : 1147 - 1154. 被引量:1
  • 5BECZE E. Manage side effects of cabazitaxel in patients with castrate- resistant prostate cancer[ J]. ONS Connect, 2012,27(9) :16 -17. 被引量:1
  • 6Cabazitaxet at 20 mg'm 2 compared to 25 mg'm 2 with predni- sone for the treatment of metastatic castration resistant prostate cancer(PROSELICA) [ EB/OL ]. http ://www. clinicahrials, gov/ et2/results? term = eabazitaxel&Search. 被引量:1
  • 7VILLANUEVA C, AWADA A, CAMPONE M,et al. A multicen- tre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer pro- gressing after anthracycline and taxane treatment: a phase Ⅰ/Ⅱ study[J]. Eur JCancer, 2011, 47(7) :1037-1045. 被引量:1
  • 8NADIM1NTY N , GAO AC. Mechanisms of persistent activationof the androgen receptor in CRPC : recent advances and futureperspectives [ J ]. World J Urol,2012 , 30 ( 3 ) : 287 - 295 . 被引量:1
  • 9ACHARYA M, BERNARD A, GONZALEZ M,ei al. Open-la-bel, phase I,pharmacokinetic studies of abiraterone acetate inhealthy men[ J ]. Cancer Chemother Pharmacol, 2012,69 ( 6 ):1583 - 1590. 被引量:1
  • 10ATTARD G, REID AH, YAP TA , et al. Phase I clinical trial ofa selective inhibitor of CYP17,abiraterone acetate, confirms thatcastration-resistant prostate cancer commonly remains hormonedriven[J], J Clin Oncol, 2008,26(28) :4563 -4571. 被引量:1

共引文献13

同被引文献41

  • 1杨艳,陈莉.前列腺癌患者去势治疗后心理障碍的原因分析及干预策略[J].上海交通大学学报(医学版),2011,31(6):730-732. 被引量:14
  • 2潘寿华,阎家峻,郑专.前列腺癌雄激素依赖转化后雄激素受体基因表达变化的研究[J].中国癌症杂志,2011,21(4):287-289. 被引量:3
  • 3张强,马合苏提,白强,杨志刚,霍日查.伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响[J].肿瘤防治研究,2014,41(2):131-133. 被引量:3
  • 4那彦群,孙颖浩.前列腺癌诊断治疗指南[M]//那彦群,叶章群,孙颖浩,等,2014版中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2014:61-89. 被引量:5
  • 5Mottet N, Bellmunt J, Bolla M,et al. EAU guidelines on prostate cancer. Part Ⅱ: Treatment of advanced, relapsing, and castra- tion-resistant prostate cancer[J ]. Eur Urol, 2011,59 : 572-583. 被引量:1
  • 6Attrd G,Reid A,Auchus R,et at. Clinical and biochemical con- sequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with ad- vanced prostate cancer [J]. J Clin Endocrinol Metab,2012,97 (2) :507-516. 被引量:1
  • 7Omlin A,J Pezaro C,Zaidi S,et al. Antitumour activity of abi- raterone and diethylstilhoestrol when administered sequentially to men with castration-resistant prostate cancer [J]. Br J Cancer, 2013,3 : 1079-1084. 被引量:1
  • 8Basch E, Autio K, Ryan C J, et al. nisone versus prednisone alone in Abiraterone acetate plus pred- chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-repor-led outcome results of a randomised phase 3 trial[J]. Lancet Oncol, 2013,14(12) : 1193-1199. 被引量:1
  • 9Ha YS,Goodin S,Dipaola RS,et al. Enzalutamide for the treat- ment of castration-resistant prostate cancer [J]. Drugs Today (Barc) ,2013,49:7-13. 被引量:1
  • 10Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer [J]. Ann Oncol, 2010,21 (11 ) : 2135-2144. 被引量:1

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部